Adaptimmune begins in-house T-cell therapy manufacture at PA plant
Technology :: Adaptimmune (ADAP)
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP)
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial :: Adaptimmune (ADAP)
Technology :: Adaptimmune (ADAP)
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP)
Adaptimmune Therapeutics plc - 5/5/2015 | TD Cowen
Asco 2021 – Adaptimmune's T-cell receptors see a route to market | Evaluate
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors | MD Anderson Cancer Center
Biotech Tour: An Inside Look at the Cell Therapy Manufacturing Process
Adaptimmune on X: "Today, we proudly announce the initiation of a rolling biologics license application (BLA) for afami-cel, our first-gen engineered TCR T-cell therapy targeting MAGE-A4. Completion of the submission is planned
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors :: Adaptimmune (ADAP)
Technology :: Adaptimmune (ADAP)
Adaptimmune and TCR² Therapeutics plan merger
Adaptimmune Therapeutics Stock Ahead Of Anticipated BLA (NASDAQ:ADAP) | Seeking Alpha
Adaptimmune Confident T-Cell Therapy Will Hit Efficacy Endpoint | BioSpace
Adaptimmune to lay off up to 30% of staff amid pipeline shift
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer | Journal for ImmunoTherapy of Cancer
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO :: Adaptimmune (ADAP)
Adaptimmune on X: "NEWS: In this release, you will find a summary of the data that will be presented in our #AACR22 poster in which we present a large screening dataset examining
MD Anderson Cancer Center :: Adaptimmune (ADAP)
Net Present Value Model: Adaptimmune Therapeutics Plc's ADPA-2M4CD8 - Market Research Reports & Consulting | GlobalData UK Ltd.
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial | Nature Medicine
adap-20211231x10k004.jpg
Adaptimmune raises US$100m - European Biotechnology
